Sabinsa Patent Infringement Litigation Against Prakruti Settled: Curcumin C3 ComplexPatent Success

BENGALURU, India - March 4, 2015 - PRLog -- Sabinsa Corporation, a subsidiary of Bangalore based Indian Multinational Health Science Company, Sami Labs Ltd which manufactures and markets Phytonutrients and standardized herbal extracts, specialty fine chemicals, and organic intermediates used in the nutritional, pharmaceutical and food industries, has successfully concluded its Patent Infringement lawsuit against Prakruti Products Private Limited. A proposed Final Consent Judgment, agreed by the parties, was submitted to the United States District Court in New Jersey on February 18, 2015.

The lawsuit, filed in the US District Court, New Jersey on July 30, 2014, alleged Prakruti was selling products that infringed upon Sabinsa’s

Curcumin C3 Complex^® US Patent 5,861,415, which protects compositions, methods of use, and methods of extraction of a nutritional supplement in the US.

In addition to any undisclosed monetary settlement, Prakruti has agreed to discontinue any and all future sales of Curcumin to outside distribution. The proposed Final Consent Judgment stipulates that the ’415 Patent was valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to Curcumin both in the United States and

Europe. In the United States, Sabinsa continues to litigate the willful infringement of the ’415 patent by HerbaKraft, Inc., NutriBioLink LLC, and Olive Lifesciences Private Limited. In Germany, Sabinsa continues to litigate a European Curcumin patent infringed by Olive Lifesciences.

"Both sides of this suit favored resolution and came to terms that were more than amicable, while the agreement also sustains Sabinsa’s Curcumin patent to the highest degree,” said

Dr. Muhammed Majeed, Founder and Chairman, Sami / Sabinsa Group. “This settlement sendsa clear message to all suppliers on foreign soil that Sabinsa is very serious about defending its’ patents. This win clearly shows that sitting in India while violating our Curcumin patent, does not mean you can escape IP theft consequences. We also see this as a win for our customers and their consumers alike, because the Curcumin C3 Complex® brand has been defended and protected."

"The consent judgment should serve as a warning to those businesses that trade on Sabinsa's efforts, investments, and innovations,” said James H. Hulme, Partner, Arent Fox LLP, the attorney who represents Sami / Sabinsa in IP infringement matters. “If you infringe on

Company's intellectual property, you will be called to account in a court of law."

Because of Sabinsa’s patent other companies can certainly sell a variety of Curcumin products, however they may not sell copy cat versions of Sabinsa’s unique composition ratio, nor market it for its antioxidant use, nor use the Ethyl Acetate extraction method developed by Sabinsa and outlined in Sabinsa’s patent.

Curcumin C³ Complex® is a Registered Trademark and Patented product of Sabinsa Corp., and is protected under U.S. Patent No. 5,861,415, and International Patents and Patents Pending.

The name C3 Complex was chosen to represent the ingredient’s three main chemical compounds: Curcumin, Demethoxycurcumin & Bisdemethoxycurcumin, collectively known as Curcuminoids. Curcumin C³ Complex® is a specific mixture of Curcuminoids, making it a unique form of Curcumin quite different from generic Curcumin extracts. It has been used in more clinical studies than any other Curcumin ingredient in the world.

About Sami Labs Ltd.

“The vision of a research scientist and a passionate entrepreneur takes on social and commercial expressions.” This, in short, explains the genesis and growth of Sami Labs”

Dr. Muhammed Majeed established Sabinsa Corporation during the year 1988 in the state of New Jersey, USA with the objective of importing and marketing generic drugs into the US for the drug molecules coming off patent. Very soon he introduced into the US market a new line of products based on Indian herbal plants. It was Dr. Majeed who introduced to the Americans that Ayurveda from India can act as a complete curative to their various ailments. The persistent efforts made by Dr. Majeed in the early nineties in the field of Ayurveda did reap benefits among the Americans. To facilitate the increased demand for innovative application-based products, Sami Labs Limited (formerly known as Sami Chemicals & Extracts Limited) was set up in 1991 in Bangalore as a research and development facility. Today the main thrust and focus of Sami is on new product development and market oriented research. To cater to the expanding global market, Sami Labs has fully owned subsidiaries in USA, Europe, Japan, Australia, Malaysia, Philippines, Vietnam, UAE, China, Russia and South Korea.

About Sabinsa Corporation:

Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 25 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 110 full time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher and Halal. For more information visit,  www.sabinsa.com, (http://www.sabinsa.com/)or contact your sales representative.

For further information please contact: media@samilabs.com